Hospital
White River Health System, INC.
White River Health System, INC. was paid $22.24M by Medicaid between Jan 2018 and Dec 2024, across 392 billing codes. Its largest line is 87502, Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets — 4.9% of everything it billed.
33Billing provider infoWHITE RIVER HEALTH SYSTEM, INC.
BATESVILLE, AR 72501
BATESVILLE, AR 72501
33aNPI1710943881assigned 04/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.24M
24GClaims1,143,511
24DCodes billed392
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#4 of 49
Median peer was paid$2.62M
This provider vs. median8.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BAXTER, SHAWNA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 148,194 | $2.30M | |
| 2019 | 181,083 | $3.11M | |
| 2020 | 168,131 | $2.81M | |
| 2021 | 166,207 | $3.67M | |
| 2022 | 169,251 | $3.71M | |
| 2023 | 167,599 | $3.62M | |
| 2024incomplete | 143,046 | $3.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.9% | 11,078 | 9,793 | $1.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 6,921 | 6,056 | $866K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 8,945 | 7,873 | $823K |
| 80053 | Comprehensive metabolic panel | 3.4% | 54,243 | 42,353 | $761K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 9,973 | 6,630 | $726K |
| 87631 | 3.1% | 6,899 | 6,386 | $698K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 17,390 | 5,067 | $586K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.3% | 43,537 | 36,903 | $515K |
| 59025 | Fetal non-stress test | 2.3% | 3,504 | 1,985 | $512K |
| 87428 | 2.3% | 8,516 | 7,615 | $505K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.1% | 1,975 | 1,816 | $466K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.0% | 4,043 | 3,595 | $448K |
380 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 3,846 | $417K |
| 64493 | 1.8% | 2,311 | $401K | |
| 87632 | 1.7% | 3,066 | $384K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 5,053 | $367K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 56,059 | $365K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 7,603 | $335K |
| 64635 | 1.5% | 2,030 | $332K | |
| 87486 | 1.4% | 6,686 | $309K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 3,720 | $304K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 4,694 | $296K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 19,773 | $282K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 2,014 | $251K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 18,384 | $250K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 744 | $246K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.0% | 782 | $231K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 1,626 | $224K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,275 | $208K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,145 | $200K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,173 | $198K |
| 99283 | Emergency room visit (moderate) | <1% | 9,217 | $193K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 521 | $191K |
| 87581 | <1% | 3,633 | $166K | |
| 87503 | <1% | 6,214 | $162K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,139 | $160K |
| 83880 | <1% | 9,246 | $159K | |
| 97162 | <1% | 2,558 | $154K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,668 | $149K |
| 80050 | General health panel | <1% | 3,199 | $144K |
| 36415 | Collection of venous blood by venipuncture | <1% | 69,204 | $133K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,702 | $131K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,089 | $126K |
| 84484 | <1% | 20,497 | $121K | |
| 80305 | <1% | 13,668 | $115K | |
| 51701 | <1% | 1,190 | $111K | |
| 72141 | <1% | 476 | $107K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,191 | $107K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,345 | $104K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,616 | $103K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,324 | $102K |
| 72131 | <1% | 1,122 | $102K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,164 | $99K |
| 64490 | <1% | 597 | $97K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,710 | $95K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 478 | $90K |
| 87150 | <1% | 1,880 | $88K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,993 | $88K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,469 | $87K |
| 36591 | <1% | 2,591 | $87K | |
| 62323 | <1% | 888 | $86K | |
| 81001 | <1% | 29,117 | $86K | |
| 85027 | <1% | 17,920 | $82K | |
| 86901 | <1% | 3,351 | $82K | |
| 71250 | <1% | 1,118 | $81K | |
| 80061 | Lipid panel | <1% | 8,069 | $77K |
| 62370 | <1% | 3,066 | $76K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,653 | $73K |
| 87040 | <1% | 8,813 | $72K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 620 | $72K |
| 20610 | <1% | 709 | $70K | |
| 73630 | <1% | 3,107 | $67K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,665 | $67K |
| 99284 | Emergency room visit (serious) | <1% | 4,174 | $65K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 2,407 | $65K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,627 | $64K |
| 83690 | <1% | 10,022 | $63K | |
| 73221 | <1% | 266 | $63K | |
| 80377 | <1% | 4,102 | $63K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,647 | $62K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 720 | $62K |
| 64633 | <1% | 458 | $62K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,627 | $61K |
| 83605 | <1% | 7,656 | $58K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 445 | $57K |
| 82962 | <1% | 16,521 | $56K | |
| 64494 | <1% | 1,938 | $55K | |
| 93458 | <1% | 829 | $54K | |
| 84145 | <1% | 4,046 | $53K | |
| 12001 | <1% | 250 | $52K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 1,622 | $51K |
| 99285 | Emergency room visit (most serious) | <1% | 2,271 | $51K |
| 74018 | <1% | 2,781 | $51K | |
| 70486 | <1% | 450 | $50K | |
| 81025 | <1% | 6,636 | $50K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 239 | $50K |
| 82550 | <1% | 12,007 | $48K | |
| 87077 | <1% | 6,507 | $48K | |
| 73562 | <1% | 1,777 | $48K | |
| 64636 | <1% | 1,793 | $48K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,148 | $47K |
| G0378 | Hospital observation service, per hour | <1% | 4,850 | $46K |
| 96401 | <1% | 525 | $45K | |
| 73130 | <1% | 2,153 | $45K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,473 | $42K |
| 73610 | <1% | 2,737 | $42K | |
| 73030 | <1% | 2,498 | $41K | |
| 73110 | <1% | 2,046 | $40K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,313 | $39K |
| C1769 | Guide wire | <1% | 1,114 | $38K |
| 93971 | <1% | 1,095 | $38K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 174 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,869 | $36K |
| 82728 | <1% | 3,205 | $36K | |
| 84703 | <1% | 4,170 | $35K | |
| 73560 | <1% | 1,884 | $34K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,253 | $34K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 829 | $33K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,552 | $33K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,770 | $31K |
| 87634 | <1% | 388 | $31K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 319 | $30K |
| 87807 | <1% | 2,733 | $30K | |
| 87186 | <1% | 6,232 | $30K | |
| 95886 | <1% | 612 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,898 | $28K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 2,473 | $28K |
| 82150 | <1% | 4,863 | $28K | |
| 86140 | <1% | 4,427 | $28K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 668 | $28K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,111 | $28K |
| 85610 | <1% | 11,486 | $27K | |
| 64495 | <1% | 1,280 | $26K | |
| 97165 | <1% | 578 | $26K | |
| 93017 | <1% | 1,606 | $26K | |
| 83735 | <1% | 6,737 | $26K | |
| 29125 | <1% | 105 | $25K | |
| 69421 | <1% | 156 | $25K | |
| 84439 | <1% | 3,018 | $25K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,492 | $25K |
| 86900 | <1% | 3,356 | $23K | |
| 86885 | <1% | 2,428 | $23K | |
| 73502 | <1% | 1,445 | $23K | |
| 87070 | <1% | 2,590 | $23K | |
| 94010 | <1% | 1,176 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,749 | $22K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,422 | $21K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,135 | $21K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 209 | $21K |
| 95811 | <1% | 165 | $20K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,123 | $20K |
| 27096 | <1% | 125 | $20K | |
| 83550 | <1% | 2,827 | $20K | |
| 82803 | <1% | 1,627 | $19K | |
| 87641 | <1% | 1,118 | $19K | |
| 90715 | <1% | 1,191 | $19K | |
| 72110 | <1% | 657 | $19K | |
| 82565 | <1% | 1,496 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,229 | $19K |
| 72100 | <1% | 935 | $19K | |
| 82607 | <1% | 1,866 | $18K | |
| 84702 | <1% | 1,749 | $18K | |
| 77066 | Tomosynthesis, mammo | <1% | 268 | $17K |
| 96367 | <1% | 1,763 | $17K | |
| 85652 | <1% | 4,758 | $16K | |
| 76642 | <1% | 567 | $16K | |
| 64491 | <1% | 433 | $16K | |
| 85007 | <1% | 4,099 | $15K | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 452 | $15K |
| 83540 | <1% | 3,134 | $15K | |
| 82378 | <1% | 891 | $15K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 70 | $14K |
| 90697 | <1% | 881 | $13K | |
| 77080 | <1% | 356 | $13K | |
| 85378 | <1% | 2,347 | $12K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 312 | $12K |
| 80364 | <1% | 518 | $12K | |
| 86235 | <1% | 309 | $12K | |
| 71020 | <1% | 1,203 | $11K | |
| 84100 | <1% | 4,887 | $11K | |
| 93922 | <1% | 570 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 163 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 283 | $11K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 539 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 282 | $11K |
| 62321 | <1% | 32 | $10K | |
| 85384 | <1% | 1,160 | $10K | |
| 81002 | <1% | 4,951 | $10K | |
| 73590 | <1% | 508 | $10K | |
| 83655 | <1% | 639 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,894 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 769 | $10K |
| 90680 | <1% | 747 | $10K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 74 | $9K |
| 80376 | <1% | 457 | $9K | |
| 97001 | <1% | 206 | $9K | |
| 82746 | <1% | 827 | $9K | |
| 64492 | <1% | 355 | $8K | |
| 93880 | <1% | 301 | $8K | |
| 94060 | <1% | 280 | $8K | |
| 94760 | <1% | 1,067 | $8K | |
| 72128 | <1% | 59 | $8K | |
| 94729 | <1% | 480 | $8K | |
| 73090 | <1% | 472 | $7K | |
| 64483 | <1% | 91 | $7K | |
| 84550 | <1% | 1,574 | $7K | |
| 86038 | <1% | 613 | $6K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 155 | $6K |
| 96415 | <1% | 350 | $6K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 200 | $6K |
| 85730 | <1% | 1,564 | $6K | |
| 87640 | <1% | 454 | $6K | |
| 73140 | <1% | 384 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,346 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,097 | $6K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,491 | $6K |
| 80320 | <1% | 413 | $6K | |
| 74022 | <1% | 220 | $6K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 98 | $6K |
| 36430 | <1% | 118 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,077 | $5K |
| 80076 | <1% | 514 | $5K | |
| 82570 | <1% | 1,224 | $5K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 53 | $5K |
| 90677 | <1% | 396 | $5K | |
| 90633 | <1% | 394 | $5K | |
| 84156 | <1% | 1,465 | $5K | |
| 51702 | <1% | 72 | $4K | |
| 94761 | <1% | 779 | $4K | |
| 76775 | <1% | 241 | $4K | |
| 87400 | <1% | 979 | $4K | |
| 73080 | <1% | 225 | $4K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 49 | $4K |
| 76536 | <1% | 83 | $4K | |
| 70496 | <1% | 32 | $4K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 917 | $4K |
| 86160 | <1% | 347 | $4K | |
| 64634 | <1% | 261 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,930 | $4K |
| 97166 | <1% | 116 | $3K | |
| 73070 | <1% | 216 | $3K | |
| 73700 | <1% | 45 | $3K | |
| A6248 | Hydrogel dressing, wound filler, gel, per fluid ounce | <1% | 506 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,353 | $3K |
| 74019 | <1% | 134 | $3K | |
| 43235 | <1% | 23 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,176 | $3K |
| 96376 | <1% | 4,413 | $3K | |
| 94618 | <1% | 173 | $3K | |
| 20605 | <1% | 26 | $3K | |
| 90686 | <1% | 316 | $3K | |
| 86431 | <1% | 586 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 311 | $3K |
| 86200 | <1% | 205 | $3K | |
| 90710 | <1% | 200 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 725 | $2K |
| 74000 | <1% | 230 | $2K | |
| 86308 | <1% | 402 | $2K | |
| 70498 | <1% | 17 | $2K | |
| 29580 | <1% | 287 | $2K | |
| 71010 | <1% | 770 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 316 | $2K |
| 72170 | <1% | 140 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 185 | $2K |
| 86225 | <1% | 164 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,746 | $2K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 69 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,001 | $2K |
| 82040 | <1% | 1,698 | $2K | |
| 87045 | <1% | 164 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 87340 | <1% | 143 | $2K | |
| 88720 | <1% | 266 | $2K | |
| 64640 | <1% | 87 | $2K | |
| 71271 | <1% | 53 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,965 | $2K |
| 86803 | <1% | 126 | $2K | |
| 90698 | <1% | 102 | $2K | |
| 84480 | <1% | 204 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 49 | $1K |
| 86317 | <1% | 126 | $1K | |
| 85018 | <1% | 813 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,345 | $1K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 31 | $1K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,539 | $1K |
| 86003 | <1% | 15 | $1K | |
| 82247 | <1% | 227 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 41 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,552 | $1K |
| 73120 | <1% | 122 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,602 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,342 | $1K |
| 80074 | <1% | 12 | $1K | |
| 86704 | <1% | 103 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,339 | $1K |
| 90716 | <1% | 76 | $985.50 | |
| 83615 | <1% | 268 | $979.89 | |
| 90707 | <1% | 75 | $972.36 | |
| 82248 | <1% | 207 | $920.51 | |
| 82731 | <1% | 12 | $919.80 | |
| 72050 | <1% | 28 | $903.27 | |
| 97161 | <1% | 105 | $900.66 | |
| 90696 | <1% | 80 | $893.52 | |
| 71101 | <1% | 78 | $882.52 | |
| 95911 | <1% | 16 | $866.40 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 13 | $858.26 |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $851.64 |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 82 | $845.46 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 469 | $797.13 |
| 36600 | <1% | 619 | $778.09 | |
| 72040 | <1% | 26 | $686.66 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 18 | $672.00 |
| G0008 | Administration of influenza virus vaccine | <1% | 283 | $657.76 |
| 93296 | <1% | 82 | $654.14 | |
| 84481 | <1% | 30 | $630.87 | |
| 92587 | <1% | 16 | $619.56 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 542 | $619.08 |
| 73620 | <1% | 47 | $611.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 160 | $593.15 |
| 86592 | <1% | 156 | $586.61 | |
| 76870 | <1% | 14 | $555.83 | |
| 80069 | <1% | 49 | $511.75 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $508.20 |
| 87046 | <1% | 163 | $474.33 | |
| 93308 | <1% | 18 | $445.81 | |
| J3490 | Unclassified drugs | <1% | 313 | $443.40 |
| 93970 | <1% | 30 | $425.92 | |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | <1% | 61 | $399.74 |
| 84436 | <1% | 87 | $391.60 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 590 | $382.11 |
| 71100 | <1% | 32 | $369.76 | |
| L4387 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 83 | $358.25 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 532 | $352.38 |
| 84165 | <1% | 44 | $341.37 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 131 | $318.41 |
| 83090 | <1% | 14 | $316.45 | |
| 82553 | <1% | 33 | $281.48 | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 997 | $267.49 |
| 87209 | <1% | 12 | $259.50 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 23 | $256.48 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 232 | $253.71 |
| 93325 | <1% | 25 | $252.96 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 580 | $252.68 |
| 71047 | <1% | 14 | $250.83 | |
| 12002 | <1% | 20 | $250.00 | |
| A6456 | Zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 87 | $247.97 |
| C1874 | Stent, coated/covered, with delivery system | <1% | 14 | $245.76 |
| 85014 | <1% | 245 | $238.94 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 227 | $231.85 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 54 | $229.56 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 382 | $213.23 |
| 84630 | <1% | 29 | $201.91 | |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | <1% | 92 | $162.40 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $154.42 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,034 | $153.15 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 746 | $150.61 |
| 76942 | <1% | 668 | $148.77 | |
| 90656 | <1% | 12 | $144.32 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 410 | $142.55 |
| 83921 | <1% | 14 | $129.01 | |
| 87177 | <1% | 12 | $127.10 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 60 | $116.32 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 476 | $104.27 |
| 82043 | <1% | 77 | $99.24 | |
| 64484 | <1% | 15 | $90.03 | |
| 82947 | <1% | 15 | $71.73 | |
| 99218 | <1% | 36 | $58.12 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 34 | $55.62 |
| 82009 | <1% | 14 | $45.22 | |
| 86923 | <1% | 18 | $34.00 | |
| Q3014 | Telehealth originating site facility fee | <1% | 26 | $32.42 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 284 | $30.18 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 45 | $22.71 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 134 | $16.24 |
| 88342 | <1% | 18 | $16.24 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 51 | $15.93 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 54 | $7.85 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 807 | $3.14 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 419 | $2.13 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 180 | $0.37 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 31 | $0.02 |
| 96417 | 0% | 82 | $0.00 | |
| 82055 | 0% | 168 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 55 | $0.00 |
| G0424 | Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day | 0% | 109 | $0.00 |
| 36592 | 0% | 16 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 21 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 13 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 78 | $0.00 |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 0% | 840 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 49 | $0.00 |
| 96127 | 0% | 54 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAXTER, SHAWNA (PROVIDER ENROLLMENT)
Parent organizationWHITE RIVER HEALTH SYSTEM, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.